KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Receivables (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Change in Receivables data on record, last reported at $8.8 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 30.45% year-over-year to $8.8 million; the TTM value through Dec 2025 reached $10.7 million, up 38.64%, while the annual FY2025 figure was $10.7 million, 38.64% up from the prior year.
  • Change in Receivables reached $8.8 million in Q4 2025 per PCRX's latest filing, up from $897000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $15.8 million in Q2 2021 and bottomed at -$18.4 million in Q3 2021.
  • Average Change in Receivables over 5 years is $1.9 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: tumbled 962.6% in 2021, then soared 688.68% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $13.5 million in 2021, then crashed by 63.52% to $4.9 million in 2022, then skyrocketed by 74.56% to $8.6 million in 2023, then soared by 47.12% to $12.7 million in 2024, then crashed by 30.45% to $8.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $8.8 million in Q4 2025, $897000.0 in Q3 2025, and $9.6 million in Q2 2025.